KELARUTAN DAN STABILITAS KIMIA KOMPLEKS DIDANOSIN DENGAN NIKOTINAMID ATAU L-ARGININ
DOI:
https://doi.org/10.17146/jsmi.2014.15.2.4363Keywords:
DDI, Nikotinamid, L-arginin, Kelarutan, Stabilitas kimiaAbstract
KELARUTAN DAN STABILITAS KIMIA KOMPLEKS DIDANOSIN DENGAN NIKOTINAMID ATAU L-ARGININ. Didanosin (DDI) adalah obat anti HIV yang bekerja dengan menghambat enzim reverse transkriptase yang bertanggung jawab dalam replikasi virus HIV. Ketersediaan hayati DDI pada pemberian secara oral sangat buruk akibat
terhidrolisis dalam suasana asam. Penelitian ini bertujuan untuk mengetahui pengaruh pembentukan kompleks antara DDI dengan NKT atau ARG terhadap kelarutan dan stabilitas kimia DDI. Kompleks DDI-NKT dibuat dengan metode slurry menggunakan pelarut campuran etanol:air (7:3), sedangkan kompleks DDI-ARG dibuat dengan metode penguapan pelarut menggunakan pelarut yang sama. Karakterisasi kompleks DDI-NKT dan DDI-ARG meliputi, analisis dengan mikroskop polarisasi, difraksi sinar-X serbuk, uji kelarutan, dan stabilitas kimia pada larutan dapar pH 1,2; 4,5 dan 6,8 di suhu 37 °C.
Karakterisasi dengan mikroskop polarisasi dan difraksi sinar-X serbuk menunjukkan terbentuknya kompleks DDI-NKT dan DDI-ARG. Kelarutan kompleks DDI-ARG dan DDI-NKT dalam air berturut-turut 1,86 dan 4,54 kali lipat dari kelarutan DDI murni. Hasil uji stabilitas kimia menunjukkan larutan kompleks DDI-NKT dan DDI-ARG mengalami degradasi lebih lambat daripada DDI murni pada pH 1,2; 4,5; dan 6,8 di suhu 37°C. Hubungan linier antara pH terhadap logaritma tetapan laju degradasi (log kobs) menunjukkan, bahwa degradasi kompleks DDI-NKT, DDI-ARG, dan DDI pada pH 1,2 hingga 6,8 dikatalisis oleh asam spesifik. Hasil penelitian dapat disimpulkan, bahwa pembentukan kompleks DDI-NKT dan DDI-ARG dapat meningkatkan kelarutan dan stabilitas kimia DDI.
Downloads
References
. AHFS Drug Information®. "Didanosine." American Hospital Formulary Service, American Society of Hospital Pharmacist, Bethesda,1995.
. B.D. Anderson, M.B. Wygant, T.X. Xiang, W.A. Waugh, V. Stella. "Preformulation solubility and kinetic studies of 2',3'-dideoxypurine nucleosides: potential anti-AIDS agents." International Journal of Pharmaceutics", vol. 45, pp. 27-37. 1988.
. M.N. Nassar, T. Chen, M.J. Reff, S.N. Agharkar. "Didanosine." in Analytical Profiles Drug Substances and Excipients, vol. 22, pp. 185-227, 1991.
. J.W. Russel, L.J. Klunk. Comparative Pharmacokinetics of New Anti-HIV Agents: 2',3'- Dideoxyadenosine and 2',3'-Dideoxyinosine." Biochemical Pharmacology, vol. 38, pp. 1385-88, 1990.
. A. Jayasankar A. Somwangthanaroj, J.Z. Shao, N. Rodríguez-Hornedo. "Cocrystal Formation during Cogrinding and Storage is Mediated by Amorphous Phase". Pharmaceutical Research, vol. 23, pp. 81-92, 2006.
. C.B.Aakeroy. "Crystal Engineering: Strategies and Architectures." Acta Crystallographyca B, vol. 53, pp. 569-86, 1997.
. G.R. Desiraju, "Supramolecular Synthons in Crystal Engineering: A New Organic Synthesis." Angewandte Chemie International Edition, vol. 34, pp. 23-27, 1995.
. C.B.Aakeroy, D.J. Salmon. "Building Co- Crystals with Molecular Sense and Supramolecular Sensibility." Crystal Engineering Community, vol. 7, pp. 39-48, 2005.
. P. Vishweshar, J.A. McMahon, M. Oliveira, M. Peterson, M.J. Zaworotko. "The Predictably Elusive Form II of Aspirin". Journal of American Chemical Society, vol. 127, pp. 02-03, 2005.
. Y. Umeda, T. Fukami, T. Furuishi, T. Suzuki, M. Makimura, K. Tonomo. "Molecular Complex Consisting of Two Typical External Medicines: Intermolecular Interaction between Indomethacin and Lidocaine." Chemical Pharmaceutical Bulletin, vol. 55, pp. 832-36, 2007.
.A.V. Trask, W.D.S. Motherwell, W. Jones. "Physical Stability Enhancement of Theophylline via Cocrystallization". International Journal Pharmaceutics, vol. 320, pp. 14-23, 2006.
. M. Almarsson, M.J. Zaworotko." Crystal Engineering of the Composition of Pharmaceutical Phases. Do Pharmaceutical Co- Crystals Represent a New Path to Improved Medicines." Chemical Communications, pp. 89-96, 2004.
. J. Lu, S. Rohani. "Preparation and Characterization of Theophylline-Nicotinamide Cocrystal." Organic Process Research & Development, vol. 13, pp. 69-75,2000.
. B. Sarma, J. Chen J, H.Y., His,A.S. Myerson. "Solid forms of pharmaceuticals: Polymorphs, salts and cocrystals." Korean Journal of Chemical Engineering, vol. 28, pp. 15-22, 2011.
. N. Blagden, M. de Matas, P.T. Gavan, P. York. " Crystal Engineering of Active Pharmaceutical Ingredients to Improve Solubility and Dissolution Rates." Advance Drug Delivery Review, vol 59, pp. 17-30,2007.
. M.K. Stanton, M.K."Improved Pharmacokinetics of AMG 517 Through Co Crystallization Part 1: Comparison of Two Acids With Corresponding Amide Co-crystals." Journal of Pharmaceutical Sciences, vol 99, pp. 69-78, 2010.
. D.R. Weyna, M.L. Cheney, N. Shan, M. Hanna, M.J. Zaworotko, V. Sava, S.Song, J.R. SanchezRamos. "Improving Solubility and Pharmacokinetics of Meloxicam via MultipleComponent Crystal Formation." Molecular Pharmaceutics, vol. 9, pp. 94-102, 2012.
. J.F. Remenar, S.L. Morissette, M.L. Peterson, B. Moulton, J.M. MacPhee, H.R. Guzman, O. Almarsson. "Crystal Engineering of Novel Cocrystals of A Triazole Drug with 1,4- Dicarboxylic Acids." Journal American Chemical Society, vol. 125, pp. 8456, 2003.
. M.B. Hickey, M. Peterson, L.A. Scoppettuolo, S.L.Morrisette,A. Vetter, H. Guzman, J.F. Remenar, Z. Zhang, M.D. Tawa, S. Haley, M.J. Zaworotko, O. Almarsson. "Performance Comparison of a Co-crystal of Carbamazepine with Marketed Product." European Journal of Pharmaceutics and Biopharmaceutics, vol 67, 12-19, 2007.
. P. Sanphui, N.J. Babu, A. Nangia. "Temozolomide Cocrystals with Carboxamide Coformer." Crystal Growth & Design, vol. 13, pp. 08-19, 2013.
. J.F. Remenar, M.L. Peterson, P.W. Stephens, Z. Zhang, Y. Zimenkov, M.B. Hickey. "Celecoxib:Nicotinamide Dissociation: Using Excipients to Capture the Cocrystal's Potential." Molecular Pharmaceutics, 4, pp. 386-400, 2007.
. D.J. Berry DJ, C.C. Seaton, W. Clegg, R.W. Harrington, S.J. Coles, P.N. Horton, M.B. Hursthouse, R. Storey, W. Jones, T. Friscic, N. Blagden. "Applying Hot-stage Microscopy to Co-crystal Screening: A Study of icotinamide with Seven Active Pharmaceutical Ingredients." Crystal. Growth Design, vol. 8, pp. 697-712, 2008.
. N. Chieng, M. Hubert, D. Saville, T. Rades, J. Aaltonen. "Formation Kinetics and Stability of Carbamazepine-Nicotinamide Cocrystals Prepared by Mechanical Activation." Crystal Growth Design, vol. 9, pp. 77-86, 2009.
. W. Porter, S. Elie, A. Matzger. "Polymorphism in Carbamazepine Cocrystals". Crystal Growth Design, vol. 8, pp. 14-6, 2008.
. M.L. Cheney, N. Shan, E.R. Healey, M. Hanna, L. Wojtas, M.J. Zaworotko, V. Sava, S. Song, J.R. Sanches-Ramos. "Effects of crystal form on solubility and pharmacokinetics: a crystal engineering case study of amotrigine." Crystal Growth Design, vol. 10, pp. 394-405, 2010.
. T. Higuchi, D.A. Zuck. "Investigation of Some Complexes Formed in Solution by Caffeine. III. Interactions between Caffeine and Aspirin, PHydroxybenzoic Acid, M-Hydroxybenzoic Acid, Salicylic Acid, Salicylate Ion, and Butyl Paraben." Journal of the American Pharmaceutical Association, vol. 42, pp. 138-45, 1953.
. T. Higuchi, S. Bolton. "The Solubility and Complexing Properties of Oxytetracycline and Tetracycline III." Journal of the American Pharmaceutical Association, vol. 48, pp. 557-64, 1959.
. H.B. Kostenbauder,T. Higuchi, Journal oftheAmerican Pharmaceutical Association. Vol. 45, pp. 518- 22,1956.
. T.Higuchi, K.A. Connors. "Phase Solubility Techniques." Advance in Analytical Chemistry and Instrumentation, vol. 4, pp. 117, 1965. [30]. Neuberg, H. , "Hydrotropy." Biochemistry, vol. Z76, 107-76,1916.
. A.M. Saleh dan L.K. El-Khordagui. "Hydrotropic Agents: A New Definition." International Journal of Pharmaceutics, vol. 24, pp. 231-38, 1985.
. L.Y. Lim dan M.L. Go. "Caffeine andNicotinamide EnhancestheAqueous Solubility of theAntimalarial Agent Halofantrine." European Journal of Pharmaceutical Sciences, vol. 10, pp.17-28, 2000.
. M.P.Evstigneev, V.P. Evstigneev, A.A. Santiago, dan D.B. Davies." Effect of a Mixture of Caffeine and icotinamide on the Solubility of Vitamin (B2) in Aqueous Solution". European Journal of Pharmaceutical Sciences,vol. 28, pp. 59-66, 2006.
. N.I. Nakano dan S.J.Igarashi. "Molecular Interactions of Pyrimidines, Purines, and Some other Heteroaromatic Compounds in Aqueous Media." Biochemistry, vol. 9, pp. 577-83. 1970
. A. Hirano, T. Arakawa, dan K. Shiraki. "Arginine Increases the Solubility of Coumarin: Comparison with Salting-in and Salting-out Additives." Journal of Biochemistry, vol. 144, pp. 363-69. 2008
. A. Hirano, T. Kameda, T.Arakawa, dan K. Shiraki. "Arginine-Assisted Solubilization System for Drug Substances: Solubility Experiment and Simulation." Journal of Physical Chemistry B, Journal Physical Chemistry B, vol. 114, 13455-62. 2010.
. R. Ariki, A. Hirano, T. Arakawa, dan K. Shiraki."Arginine Increases the Solubility ofAlkyl Gallates through Interaction with the Aromatic Ring." Journal of Biochemistry, vol. 149, pp. 89-94, 2011.
. P. Shanpui, N.R. Goud, U.B.R. Khandavilli, A. Nangia. "Fast Dissolving Curcumin Cocrystals." Crystal Growth & Design, vol. 11, pp. 4135-45, 2011.
. S.Nicoli,S.Bilzi,P.Santi,M.R.Caira, J.Li,R.Bettini. "Ethyl-Paraben and Nicotinamide Mixtures: Apparent Solubility, Thermal Behavior and X-Ray Structure of the 1:1 Co- Crystal." Journal of Pharmaceutical Sciences, vol. 97, pp. 4830-39, 2008.
. D. Zhou D, W.R. Porter, G.Z.Z. Zhang. "Drug Stability and Degradation Studies", in Developing Solid Oral Dosage Forms, Part I: Theory and Techniques in the Characterization of Drug Substances and Excipients, New York: Academic Press, 1991, pp.87-124.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
